Matches in Nanopublications for { ?s ?p "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP167792.RAQ1VNIcFHqWeZAj4l6VLEo0kR9cuSLl57g_dJPG3B-Qw130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP167792.RAQ1VNIcFHqWeZAj4l6VLEo0kR9cuSLl57g_dJPG3B-Qw130_provenance.
- NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP201574.RAvGow-oto6Xe2LY-zOk3GrGW90eiP1_hWj5G7zQPCc5U130_provenance.
- NP427017.RA-xfIs4gZSZJQ4D5TqdHSG87FI7zLgh1v0yavqUnlYpk130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427017.RA-xfIs4gZSZJQ4D5TqdHSG87FI7zLgh1v0yavqUnlYpk130_provenance.
- NP888351.RA8C34hnvJ6Dagi-wLhQoOqJ6rc2JwiLF1le4E4ywcAdg130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP888351.RA8C34hnvJ6Dagi-wLhQoOqJ6rc2JwiLF1le4E4ywcAdg130_provenance.
- NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP892031.RA39no3m2iapGhAUW7ElYU7MuXxeW4OXZsxgZnqA1DUQg130_provenance.
- NP1074094.RAU2Vjzv7Z5RO_xONj49RwT7WAnIO3Ym71zY11thThlI8130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074094.RAU2Vjzv7Z5RO_xONj49RwT7WAnIO3Ym71zY11thThlI8130_provenance.
- NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074106.RAYdv5bSe-y_e0GM11f4b-6I-5uNtfoUhiNegybT3YnfM130_provenance.
- NP738274.RALqbbecsZnLrSmzy4enVkP3EB7PTbCVnQSdLr8zXEVEA130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP738274.RALqbbecsZnLrSmzy4enVkP3EB7PTbCVnQSdLr8zXEVEA130_provenance.
- NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP687508.RAMhK6Ux9ohfCq3EdQJKVg9_qdAB3MR_iSLA7s0MlTRCI130_provenance.
- NP1074097.RAtBWMdsNWFTXLcxvowPZUXyiNUGlyqSVhKUyv9KAX_y4130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074097.RAtBWMdsNWFTXLcxvowPZUXyiNUGlyqSVhKUyv9KAX_y4130_provenance.
- NP1074102.RAnvKxhA8r4HfwuJlWoaFkEECeDquJIXXJgDmyxay6yGg130_assertion description "[These observations provide a strong rationale for the combined use of RSK and PI3K pathway inhibitors to elicit favorable responses in breast cancer patients with activated RSK.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1074102.RAnvKxhA8r4HfwuJlWoaFkEECeDquJIXXJgDmyxay6yGg130_provenance.